Other Announcements: Researchers Explore Ozempic as a Potential Addiction Treatment
June 1, 2023
P&T Committee Changes
June 1, 2023
Effect on July 1, 2023 BeneCard PBF is committed to providing innovative clinical solutions, valuable trend management strategies, and the highest quality of service. We regularly conduct a review of our formulary to remain current with the ever-changing prescription drug landscape.
During this review process, we consider changes that occur with new FDA approvals (brand and generic) and the latest clinical information. This comprehensive review looks at each therapeutic category to identify clinically superior products at the lowest net cost. This process is essential in helping control pharmaceutical spend as drug costs, particularly for already costly specialty medications, increase over time. Our goal when considering updates to our formularies is to improve member health outcomes while maximizing plan savings.
July 2023 Changes
The following changes to the primary formulary will go into effect on July 1, 2023.
| Moved from Non-Preferred to Preferred | Most Common Indication/Use |
|---|---|
| NOXAFIL 300MG | Antifungal |
| MOUNJARO | Type 2 Diabetes |
BeneCard PBF appreciates your trust and support in serving your healthcare needs through your prescription benefit program. If you have any questions, please contact your BeneCard PBF Account Executive or call our Client Service Center at 1-877-587-2239.